Does ghrelin rise before meals?

Ghrelin's relationship with fasting and feeding is well established, and the LEAP2 work adds that its antagonist moves the opposite way when food is withheld. The practically important point is that the receptor's activation state depends on both ligands, so measuring ghrelin alone gives an incomplete picture.

Why is an antimicrobial peptide regulating appetite?

The name reflects the context in which LEAP2 was first described, not the full range of what it does. Proteins are routinely named for whichever activity was noticed first, and a molecule doing two unrelated jobs is common rather than surprising.

Would blocking ghrelin cause weight loss?

It has not been shown to in any licensed product, despite sustained effort. Redundancy in the systems defending against energy deficit is the usual explanation, and the receptor's other roles complicate blocking it.

Is this related to growth hormone secretagogues sold as research material?

They act at the same receptor, GHSR. That is a statement about receptor pharmacology. Nothing here is a claim about what any research material does in a person, and none of it is licensed for any use.

GLP-1 & Incretin Science

The Only Gut Hormone That Makes You Eat, and What Switches It Off

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Ghrelin is secreted by the stomach and is the only known circulating hormone that stimulates feeding. LEAP2, identified in 2017 as an endogenous antagonist of the ghrelin receptor, fully blocks that activation and its secretion is suppressed by fasting - the mirror image of ghrelin's.

Key facts

Ghrelin source: Stomach
Receptor: GHSR, the growth hormone secretagogue receptor
Direction of effect: Stimulates feeding - orexigenic
Downstream neurons: NPY and AgRP neurons
LEAP2 full name: Liver-expressed antimicrobial peptide 2
LEAP2 sources: Liver and small intestine
LEAP2 during fasting: Secretion suppressed
LEAP2 identified as GHSR antagonist: 2017 (Ge X et al., Cell Metab 2018)

Why ghrelin is structurally unusual

Almost every circulating gut hormone that reaches the appetite circuitry reduces feeding: GLP-1, PYY, cholecystokinin, amylin, GDF15. Ghrelin goes the other way. Nakazato and colleagues showed that intracerebroventricular ghrelin strongly stimulated feeding in rats and increased body weight gain, and that anti-ghrelin immunoglobulin robustly suppressed feeding - so the endogenous hormone is doing this too, not just the injected one. It also increased feeding in rats genetically deficient in growth hormone, which matters because ghrelin's receptor was originally characterised as a growth hormone secretagogue receptor. The feeding effect is not downstream of growth hormone; it is its own action.

The circuit it runs through

After central ghrelin administration, Fos protein appeared in the regions that matter most for feeding, including NPY and AgRP neurons - the same arcuate population that PYY(3-36) silences from the other direction. Antibodies and antagonists of NPY and AgRP abolished ghrelin-induced feeding, so those neurons are not merely activated but required. Ghrelin also augmented NPY gene expression and blocked leptin-induced reduction in feeding, which the authors describe as a competitive interaction between the two hormones. Two signals, one reporting stored energy and one reporting an empty stomach, converging on the same neurons with opposite effects.

The antagonist nobody was looking for

How ghrelin action is regulated remained poorly understood for years after the hormone itself was well described. Ge and colleagues reported the answer in 2017: liver-expressed antimicrobial peptide 2, a molecule named for an entirely different presumed function, is an endogenous antagonist of GHSR. It is produced in the liver and small intestine, it fully inhibits GHSR activation by ghrelin, and it blocks ghrelin's major effects in vivo - food intake, growth hormone release, and the maintenance of viable glucose levels during chronic caloric restriction. Neutralising antibodies against endogenous LEAP2 do the reverse and enhance ghrelin action.

Why the fasting behaviour is the elegant part

LEAP2 secretion is suppressed by fasting. Ghrelin rises with fasting. The two move in opposite directions on the same stimulus, so the tone at the receptor is set by a ratio rather than by either concentration alone - the agonist climbs while the antagonist withdraws, and both changes push the same way. A system regulated by opposing ligands on a single receptor has a wider dynamic range than one regulated by agonist concentration alone, and it can be tuned from two places. The authors describe this as a mechanism for fine-tuning ghrelin action in response to changing environmental conditions.

Why blocking hunger has not produced a drug

Ghrelin looks like an obvious target: it is the one signal telling the brain to eat, so blocking it should reduce eating. Ghrelin antagonists and vaccines have been pursued for two decades without producing a licensed weight-management medicine. Part of the reason is redundancy - removing one orexigenic signal leaves the rest of a system evolved to defend against energy deficit, which compensates. Part of it is that GHSR does several other things, including a role in maintaining glucose during prolonged caloric restriction that the LEAP2 work makes explicit. Blocking a receptor whose job includes preventing hypoglycaemia during starvation is not a free action.

The connection to growth hormone secretagogues

GHSR is the receptor that growth hormone secretagogues engage, which is why this pathway appears twice in this library from opposite directions. Compounds developed to stimulate that receptor for growth hormone release are engaging the same receptor LEAP2 evolved to block, and are therefore engaging a system that also drives feeding and defends glucose. Anyone reading about GHSR agonism should know that the receptor's endogenous regulation includes a dedicated antagonist, and that its physiology extends well beyond growth hormone. Nothing supplied on this site is a licensed medicine and none of this is guidance about any compound.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does ghrelin rise before meals?: Ghrelin's relationship with fasting and feeding is well established, and the LEAP2 work adds that its antagonist moves the opposite way when food is withheld. The practically important point is that the receptor's activation state depends on both ligands, so measuring ghrelin alone gives an incomplete picture.
Why is an antimicrobial peptide regulating appetite?: The name reflects the context in which LEAP2 was first described, not the full range of what it does. Proteins are routinely named for whichever activity was noticed first, and a molecule doing two unrelated jobs is common rather than surprising.
Would blocking ghrelin cause weight loss?: It has not been shown to in any licensed product, despite sustained effort. Redundancy in the systems defending against energy deficit is the usual explanation, and the receptor's other roles complicate blocking it.
Is this related to growth hormone secretagogues sold as research material?: They act at the same receptor, GHSR. That is a statement about receptor pharmacology. Nothing here is a claim about what any research material does in a person, and none of it is licensed for any use.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum